Status:
RECRUITING
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Collaborating Sponsors:
LEO Pharma
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Detailed Description
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for ...
Eligibility Criteria
Inclusion
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Patient with 2-10% BSA
- Physician Global Assessment of 2 or greater
- Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion
- ˂2 or \>10% BSA
- PGA \<2
- Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Key Trial Info
Start Date :
January 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03827876
Start Date
January 16 2019
End Date
December 15 2019
Last Update
February 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States, 08520